Accessibility Menu
 
AtaiBeckley logo

AtaiBeckley

(NASDAQ) ATAI

Current Price$3.36
Market Cap$1.22B
Since IPO (2021)-83%
5 YearN/A
1 Year+113%
1 Month-23%

AtaiBeckley Financials at a Glance

Market Cap

$1.22B

Revenue (TTM)

$4.09M

Net Income (TTM)

$660.05M

EPS (TTM)

$-2.31

P/E Ratio

-1.45

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$3.36

Volume

80,890

Open

$3.62

Previous Close

$3.36

Daily Range

$3.32 - $3.65

52-Week Range

$1.15 - $6.75

ATAI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AtaiBeckley

Industry

Pharmaceuticals

Employees

99

CEO

Srinivas G. Rao, MD, PhD

Headquarters

Amstelveen, 1183 AT, NL

ATAI Financials

Key Financial Metrics (TTM)

Gross Margin

75%

Operating Margin

-28%

Net Income Margin

-161%

Return on Equity

0%

Return on Capital

-40%

Return on Assets

-2%

Earnings Yield

-68.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.22B

Shares Outstanding

364.75M

Volume

80.89K

Short Interest

0.00%

Avg. Volume

4.61M

Financials (TTM)

Gross Profit

$3.08M

Operating Income

$114.06M

EBITDA

$113.05M

Operating Cash Flow

$102.67M

Capital Expenditure

$901.00K

Free Cash Flow

$103.58M

Cash & ST Invst.

$256.04M

Total Debt

$2.07M

AtaiBeckley Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.07M

+21420.0%

Gross Profit

$10.89M

+217940.0%

Gross Margin

10.22%

N/A

Market Cap

$1.22B

N/A

Market Cap/Employee

$22.63M

N/A

Employees

54

N/A

Net Income

$544.81M

-1298.5%

EBITDA

$6.10M

+84.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$253.97M

+575.0%

Accounts Receivable

$14.43M

+970.3%

Inventory

$0.00

N/A

Long Term Debt

$1.80M

-87.9%

Short Term Debt

$271.00K

-97.2%

Return on Assets

-2.13%

N/A

Return on Invested Capital

-39.73%

N/A

Free Cash Flow

$48.25M

-97.9%

Operating Cash Flow

$48.15M

-98.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORICORIC Pharmaceuticals, Inc.
$12.06-2.58%
IMTXImmatics N.V.
$9.37-4.09%
AMLXAmylyx Pharmaceuticals, Inc.
$13.55+0.59%
NKTRNektar Therapeutics
$68.66-3.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
ARTLArtelo Biosciences
$10.54+2.30%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.56-0.06%

Questions About ATAI

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.